Elanco Receives USDA Approval for Befrena, New Canine Dermatitis Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: NASDAQ.COM
- New Drug Approval: Elanco Animal Health announced that its new anti-IL31 monoclonal antibody injection, Befrena, has received USDA approval and is expected to launch in the first half of 2026, further solidifying its position in the veterinary dermatology market.
- Dosing Interval Advantage: Befrena offers a dosing interval of 6 to 8 weeks, providing a longer treatment window compared to the market competitor lokivetmab, which is administered every 4 to 8 weeks, potentially attracting more veterinarians and pet owners.
- Product Line Expansion: This approval marks Elanco's second dermatology product clearance in less than 18 months, with Befrena joining Zenrelia, a once-daily oral JAK inhibitor that effectively controls skin allergies, enhancing the company's product portfolio.
- Market Reaction: Despite the new drug approval, Elanco's stock closed at $22.63 on December 31, down 0.57% from the previous session, indicating that market response to the new product still requires observation.
Analyst Views on ELAN
Wall Street analysts forecast ELAN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELAN is 25.13 USD with a low forecast of 23.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 22.760
Low
23.00
Averages
25.13
High
27.00
Current: 22.760
Low
23.00
Averages
25.13
High
27.00
About ELAN
Elanco Animal Health Incorporated is an animal health company delivering products and services to prevent and treat disease in farm animals and pets. The Company's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). It has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The Company's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
